Evidence of a low prevalence of ras mutations in a large medullary thyroid cancer series

Thyroid

Volumn 23, Issue 1, 2013, Pages 50-57

  Ciampi, Raffaele ^a   Mian, Caterina ^b   Fugazzola, Laura ^c,d   Cosci, Barbara ^a   Romei, Cristina ^a   Barollo, Susi ^b   Cirello, Valentina ^c,d   Bottici, Valeria ^a   Marconcini, Giulia ^a   Rosa, Pelizzo Maria ^b   Borrello, Maria Grazia ^e   Basolo, Fulvio ^a   Ugolini, Clara ^a   Materazzi, Gabriele ^a   Pinchera, Aldo ^a   Elisei, Rossella ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d IRCCS   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RET; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ASSESSMENT; CODON; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, MEDULLARY; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENES, RAS; GTP PHOSPHOHYDROLASES; HUMANS; ITALY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; POINT MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84872058009     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0207     Document Type: Article

References (46)

1. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB 2005 RET protooncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15:531-544. (Pubitemid 40993726)
2. Cerrato A, De Falco V, Santoro M 2009 Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J Mol Endocrinol 43:143-155.
3. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A 2007 RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92:4725-4729. (Pubitemid 350223450)
4. Drosten M, Putzer BM 2006 Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat Clin Pract Oncol 3:564-574. (Pubitemid 44781726)
5. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A, et al. 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237-241. (Pubitemid 24060936)
6. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F 1996 Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 81:1619-1622. (Pubitemid 26118602)
7. Zedenius J, Larsson C, Bergholm U, Bovee J, Svensson A, Hallengren B, Grimelius L, Backdahl M, Weber G, Wallin G 1995 Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 80:3088-3090.
8. Schilling T, Burck J, Sinn HP, Clemens A, Otto HF, Hoppner W, Herfarth C, Ziegler R, Schwab M, Raue F 2001 Prognostic value of codon 918 (ATG/ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 95:62-66.
9. Moura MM, Cavaco BM, Pinto AE, Domingues R, Santos JR, Cid MO, Bugalho MJ, Leite V 2009 Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 100:1777-1783.
10. Mian C, Pennelli G, Barollo S, Cavedon E, Nacamulli D, Vianello F, Negro I, Pozza G, Boschin IM, Pelizzo MR, Rugge M, Mantero F, Girelli ME, Opocher G 2011 Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification. Eur J Endocrinol 164:971-976.
11. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A 2008 Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682-687. (Pubitemid 351398539)
12. Ciampi R, Romei C, Cosci B, Vivaldi A, Bottici V, Renzini G, Ugolini C, Tacito A, Basolo F, Pinchera A, Elisei R 2011 Chromosome 10 and RET gene copy number alterations in hereditary and sporadic medullary thyroid carcinoma. Mol Cell Endocrinol 348:176-182.
13. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D 2011 RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11:761-774.
14. Bos JL 1989 Ras oncogenes in human cancer: a review. Cancer Res 49:4682-4689. (Pubitemid 19213607)
15. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, 2nd, Tallini G, Kroll TG, Nikiforov YE 2003 RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88:2318-2326. (Pubitemid 36549913)
16. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C 2003 Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88:2745-2752. (Pubitemid 36724451)
17. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE 2003 Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120:71-77. (Pubitemid 37046372)
18. Rapa I, Saggiorato E, Giachino D, Palestini N, Orlandi F, Papotti M, Volante M 2011 Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. J Clin Endocrinol Metab 96:2146-2153.
19. Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E, Iacconi P, Miccoli P, Pacini F 2000 N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10:19-23. (Pubitemid 30090361)
20. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Katsuragi K, Kinoshita M, Saito S, Itakura M 1992 Ras mutations in endocrine tumors: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Jpn J Cancer Res 83:1057-1062.
21. Horie H, Yokogoshi Y, Tsuyuguchi M, Saito S 1995 Point mutations of ras and Gs alpha subunit genes in thyroid tumors. Jpn J Cancer Res 86:737-742.
22. Fenton C, Anderson J, Lukes Y, Dinauer CA, Tuttle RM, Francis GL 1999 Ras mutations are uncommon in sporadic thyroid cancer in children and young adults. J Endocrinol Invest 22:781-789.
23. Bockhorn M, Frilling A, Kalinin V, Schroder S, Broelsch CE 2000 Absence of H-and K-ras oncogene mutations in sporadic medullary thyroid carcinoma. Exp Clin Endocrinol Diabetes 108:49-53. (Pubitemid 30160435)
24. Moley JF, Brother MB, Wells SA, Spengler BA, Biedler JL, Brodeur GM 1991 Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers. Cancer Res 51:1596-1599.
25. Dockhorn-Dworniczak B, Caspari S, Schroder S, Bocker W, Dworniczak B 1990 [Demonstration of activated oncogenes of the ras family in human thyroid tumors using the polymerase chain reaction]. Verh Dtsch Gas Pathol 74:415-418.
26. Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, Salama S, Al-Muhayawi S, Chaudhary A, Hamour O, Abuzenadah A, Gari M, Al-Qahtani M 2011 Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Anticancer Res 31:4179-4183.
27. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI 2009 Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801.
28. Okazaki M, Miya A, Tanaka N, Miki T, Yamamoto M, Motomura K, Miyauchi A, Mori T, Takai S 1989 Allele loss on chromosome 10 and point mutation of ras oncogenes are infrequent in tumors of MEN 2A. Henry Ford Hosp Med J 37:112-115. (Pubitemid 20207541)
29. Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, Gazouli M 2008 BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res 28:305-308. (Pubitemid 351362917)
30. Moura MM, Cavaco BM, Pinto AE, Leite V 2011 High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 96:E863-E868.
31. Mian C, Pennelli G, Fassan M, Balistreri M, Barollo S, Cavedon E, Galuppini F, Pizzi M, Vianello F, Pelizzo MR, Girelli M, Rugge M, Opocher G 2012 microRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Thyroid 22:890-896.
32. Greene FL, American Joint Committee on Cancer ACS 2002 AJCC Cancer Staging Handbook: from the AJCC Cancer Staging Manual, 6th edn. Springer-Verlag, New York.
33. Elisei R 2008 Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Pract Clin Endocrinol Metab 22:941-953.
34. Elisei R, Cosci B, Romei C, Agate L, Piampiani P, Miccoli P, Berti P, Basolo F, Ugolini C, Ciampi R, Nikiforov Y, Pinchera A 2004 Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J Clin Endocrinol Metab 89:5823-5827. (Pubitemid 39518477)
35. Cosci B, Vivaldi A, Romei C, Gemignani F, Landi S, Ciampi R, Tacito A, Molinaro E, Agate L, Bottici V, Cappagli V, Viola D, Piaggi P, Vitti P, Pinchera A, Elisei R 2011 In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Endocr Relat Cancer 18:603-612.
36. Hrafnkelsson J, Jonasson JG, Sigurdsson G, Sigvaldason H, Tulinius H 1988 Thyroid cancer in Iceland 1955-1984. Acta Endocrino (Copenh) 118:566-572.
37. Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV 2006 Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 34:1317-1325.
38. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE 2006 Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 91:3603-3610. (Pubitemid 44402144)
39. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262. (Pubitemid 40896444)
40. Ciampi R, Nikiforov YE 2005 Alterations of the BRAF gene in thyroid tumors. Endocrine Pathol 16:163-172. (Pubitemid 41687187)
41. Takahashi C, Contreras B, Iwanaga T, Takegami Y, Bakker A, Bronson RT, Noda M, Loda M, Hunt JL, Ewen ME 2006 Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor. Nat Genet 38:118-123. (Pubitemid 43011892)
42. Biscolla RP, Ugolini C, Sculli M, Bottici V, Castagna MG, Romei C, Cosci B, Molinaro E, Faviana P, Basolo F, Miccoli P, Pacini F, Pinchera A, Elisei R 2004 Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid 14:946-952. (Pubitemid 39612913)
43. Wong RL, Kazaure HS, Roman SA, Sosa JA 2012 Simultaneous medullary and differentiated thyroid cancer: a population-level analysis of an increasingly common entity. Ann Surg Oncol 19:2635-2642.
44. Romei C, Ugolini C, Cosci B, Torregrossa L, Vivaldi A, Ciampi R, Tacito A, Basolo F, Materazzi G, Miccoli P, Vitti P, Pinchera A, Elisei R 2012 Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid 22:476-481.
45. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF 2005 Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077-6084. (Pubitemid 41606528)
46. Tidyman WE, Rauen KA 2008 Noonan, Costello and cardiofaciocutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev Mol Med 10:e37.